Developer docs
API playgroundTry for free, no card

Search company profiles

Conformal Medical

Full company profile

uuid00008dr

Namestring
Conformal Medical
Legal namestring
Conformal Medical, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Conformal Medical is a privately held medical device company developing left atrial appendage occlusion (LAAO) devices for stroke prevention in patients with non-valvular atrial fibrillation. The company is targeting the more than 6 million people in the U.S. with atrial fibrillation (a population projected to exceed 12 million cases by 2030) who are at increased risk of stroke. End users of the device are interventional cardiologists and cardiac electrophysiologists performing LAAO procedures in hospital cardiac centers. Founded in 2016 and headquartered in Nashua, New Hampshire, Conformal Medical was acquired by W. L. Gore & Associates in January 2026 and now operates as part of Gore's endovascular franchise.

The company's core product is the CLAAS AcuFORM System, a next-generation LAAO device featuring a proprietary conformable foam matrix implant combined with a nitinol endoskeleton. It is the first and only LAAO device to use foam technology to seal the left atrial appendage. The device is produced in only two sizes (versus the multiple sizes required by incumbent devices such as WATCHMAN and Amulet), enabling simplified sizing, off-axis positioning, seal testing with angiography, and procedures under conscious sedation without transesophageal echocardiography (TEE). These features are intended to support same-day outpatient procedures without general anesthesia. The portfolio also includes the original CLAAS System, and clinical evidence is being generated through the CONFORM Pivotal Trial (randomized vs. WATCHMAN and Amulet in ~1,600 patients), the GLACE Study, the Conformal Early Feasibility Study, and the Conformal Prague Study. The leadership team controls a substantial patent estate, with Chairman/CMO Aaron Kaplan holding 65 U.S. patents (National Academy of Inventors, Class of 2015) and CSO Carol Devellian an inventor on 30+ issued U.S. patents.

Conformal Medical is pre-commercial and has not generated product revenue. Its go-to-market is centered on clinical trial enrollment at hospital sites in the U.S. (CONFORM Pivotal Trial, EFS) and Europe (GLACE Study, Prague Study, EU arm of CONFORM), with investigational devices supplied only to participating centers. Upon FDA pre-market approval, the documented plan is to monetize via direct sales of hardware to hospitals and physicians performing LAAO procedures, supported by clinical-site relationships built during the trial program. The company raised approximately $161 million across four rounds, including an $85 million Series C in 2020, a $35 million Series D in 2023 led by SPRIG Equity, and a $32 million Series D extension in August 2025. The January 2026 acquisition by W. L. Gore & Associates shifts commercialization to Gore's established global endovascular distribution network.

Short descriptiontext

Conformal Medical is a pre-commercial medical device company developing the CLAAS AcuFORM System, a proprietary foam-based left atrial appendage occlusion device designed to reduce stroke risk in patients with non-valvular atrial fibrillation. The company was acquired by W. L. Gore & Associates in January 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNashua, United States
HQ citystring
Nashua
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
left atrial appendage occlusion, structural heart implants, cardiac medical devices, stroke prevention devices, atrial fibrillation treatment
Industry1 code
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Cardiac Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales (Planned)
TypeHardware Sales
Description

Conformal Medical is developing its CLAAS AcuFORM System for left atrial appendage occlusion. Once FDA pre-market approval is obtained, the company plans to generate revenue through direct sales of the LAAO device to hospitals and physicians performing stroke prevention procedures in atrial fibrillation patients.

conformalmedical.com
2Clinical Trial Services
TypeProfessional Services
Description

The company conducts clinical trials (CONFORM Pivotal Trial, GLACE Study) at hospital sites, generating revenue through clinical site management and device supply for investigational use.

prnewswire.co.uk
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Others, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1CLAAS
Description

The first & only LAAO device to use conformable foam to seal the left atrial appendage. Designed to reduce the risk of stroke without the need for anticoagulants.

conformalmedical.com
+1 more record
Core offering1 text field

Conformal Medical develops the CLAAS AcuFORM System, a next-generation left atrial appendage occlusion (LAAO) implant for stroke prevention in patients with non-valvular atrial fibrillation. The device combines a proprietary conformable foam matrix with a nitinol endoskeleton and is offered in only two sizes, eliminating the need for transesophageal echocardiography, general anesthesia, and overnight hospitalization. The product is currently investigational and is being evaluated in the CONFORM Pivotal Trial and GLACE Study to support FDA pre-market approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Same-day LAAO procedures without general anesthesia or overnight hospitalization
+2 more records
Product overview1 text field

Conformal Medical is a privately held medical device company developing left atrial appendage occlusion (LAAO) technology for stroke prevention in atrial fibrillation patients. The core portfolio includes the CLAAS System (first foam-based LAAO device) and its next-generation iteration, the CLAAS AcuFORM System featuring a proprietary foam matrix with nitinol endoskeleton that requires only two sizes. Both devices are designed to seal the LAA without requiring anticoagulants and enable same-day procedures without general anesthesia or TEE. The company is actively conducting multiple clinical trials including the CONFORM Pivotal Trial and GLACE Study. Conformal Medical was acquired by W.L. Gore & Associates in early 2026.

Product and service1 record
1CLAAS AcuFORM System
CategoryCardiac Implant Devices
Description

Next-generation left atrial appendage occlusion (LAAO) device featuring a proprietary foam matrix implant with nitinol endoskeleton designed to conform to patient anatomy. Offered in only two sizes, enabling simplified same-day procedures without general anesthesia or transesophageal echocardiography (TEE). Intended for stroke prevention in patients with non-valvular atrial fibrillation as an alternative to long-term oral anticoagulation. Currently investigational and limited to clinical trial use.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-05
Description

W.L. Gore & Associates entered into a definitive agreement to acquire Conformal Medical in January 2026 for an undisclosed amount. The acquisition expands Gore's endovascular portfolio and adds the CLAAS AcuFORM next-generation LAAO technology to Gore's cardiac product line. Transaction expected to close in early 2026 pending regulatory approval. Gore generates approximately $5.3 billion in annual revenues.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Boston Scientific markets the WATCHMAN family of left atrial appendage closure devices, the leading LAAO product against which CLAAS AcuFORM is directly being compared in the CONFORM Pivotal Trial. Both companies target interventional cardiologists and electrophysiologists performing LAAO procedures for stroke prevention in non-valvular AFib patients.

2Abbott
TypeDirect peer
Description

Abbott markets the Amplatzer Amulet LAA Occluder, the second major percutaneous LAAO device competing in the same clinical indication as Conformal's CLAAS AcuFORM. Both compete head-to-head in the CONFORM Pivotal Trial and target the same AFib stroke prevention patient population.

TypeDirect peer
Description

AtriCure's AtriClip is a surgical left atrial appendage exclusion device used as an alternative to percutaneous LAAO for stroke prevention in AFib patients. Both companies target the same LAA closure clinical indication, though AtriCure is primarily used in surgical epicardial settings rather than transcatheter procedures.

TypeEmerging player
Description

SentreHEART developed the LARIAT suture-based LAA ligation system as an alternative approach to LAA closure. Both companies address the same underlying clinical need (LAA closure for AFib stroke prevention) using different mechanical approaches, and SentreHEART represents an emerging alternative modality.

TypeRegional player
Description

Lifetech Scientific (Shenzhen, China) markets the LAmbre LAA occluder, a transcatheter LAAO device competing in the same clinical indication as CLAAS AcuFORM. Lifetech is a regional player with primary commercial strength in Asia, while Conformal focuses on the US and EU markets.

TypeEmerging player
Description

Occlutech offers an LAA Occluder as part of its broader structural heart occlusion portfolio. Both companies target the same LAAO clinical indication for AFib-related stroke prevention, and Occlutech represents an emerging player with primarily European commercial reach.

TypeBroad incumbent
Description

W.L. Gore & Associates acquired Conformal Medical in January 2026 to add the CLAAS AcuFORM System to its endovascular portfolio. Gore is a broad incumbent in medical devices with established cardiac, vascular, and structural heart product lines that provide infrastructure for Conformal's commercialization.

TypeBroad incumbent
Description

Medtronic is a broad incumbent in cardiovascular devices with structural heart and cardiac surgery franchises. While Medtronic does not have a dedicated LAAO device competing head-to-head, its scale and hospital relationships make it a relevant comparable for the structural heart space Conformal operates in.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Conformal Medical

Cardiac Medical Devicesconformalmedical.com

Conformal Medical is a pre-commercial medical device company developing the CLAAS AcuFORM System, a proprietary foam-based left atrial appendage occlusion device designed to reduce stroke risk in patients with non-valvular atrial fibrillation. The company was acquired by W. L. Gore & Associates in January 2026.

What Conformal Medical does

Conformal Medical is a privately held medical device company developing left atrial appendage occlusion (LAAO) devices for stroke prevention in patients with non-valvular atrial fibrillation. The company is targeting the more than 6 million people in the U.S. with atrial fibrillation (a population projected to exceed 12 million cases by 2030) who are at increased risk of stroke. End users of the device are interventional cardiologists and cardiac electrophysiologists performing LAAO procedures in hospital cardiac centers. Founded in 2016 and headquartered in Nashua, New Hampshire, Conformal Medical was acquired by W. L. Gore & Associates in January 2026 and now operates as part of Gore's endovascular franchise.

The company's core product is the CLAAS AcuFORM System, a next-generation LAAO device featuring a proprietary conformable foam matrix implant combined with a nitinol endoskeleton. It is the first and only LAAO device to use foam technology to seal the left atrial appendage. The device is produced in only two sizes (versus the multiple sizes required by incumbent devices such as WATCHMAN and Amulet), enabling simplified sizing, off-axis positioning, seal testing with angiography, and procedures under conscious sedation without transesophageal echocardiography (TEE). These features are intended to support same-day outpatient procedures without general anesthesia. The portfolio also includes the original CLAAS System, and clinical evidence is being generated through the CONFORM Pivotal Trial (randomized vs. WATCHMAN and Amulet in ~1,600 patients), the GLACE Study, the Conformal Early Feasibility Study, and the Conformal Prague Study. The leadership team controls a substantial patent estate, with Chairman/CMO Aaron Kaplan holding 65 U.S. patents (National Academy of Inventors, Class of 2015) and CSO Carol Devellian an inventor on 30+ issued U.S. patents.

Conformal Medical is pre-commercial and has not generated product revenue. Its go-to-market is centered on clinical trial enrollment at hospital sites in the U.S. (CONFORM Pivotal Trial, EFS) and Europe (GLACE Study, Prague Study, EU arm of CONFORM), with investigational devices supplied only to participating centers. Upon FDA pre-market approval, the documented plan is to monetize via direct sales of hardware to hospitals and physicians performing LAAO procedures, supported by clinical-site relationships built during the trial program. The company raised approximately $161 million across four rounds, including an $85 million Series C in 2020, a $35 million Series D in 2023 led by SPRIG Equity, and a $32 million Series D extension in August 2025. The January 2026 acquisition by W. L. Gore & Associates shifts commercialization to Gore's established global endovascular distribution network.

Conformal Medical firmographics

Firmographics
Name
Conformal Medical
Legal name
Conformal Medical, Inc.
Website
https://conformalmedical.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
51–100 employees
Short description
Conformal Medical is a pre-commercial medical device company developing the CLAAS AcuFORM System, a proprietary foam-based left atrial appendage occlusion device designed to reduce stroke risk in patients with non-valvular atrial fibrillation. The company was acquired by W. L. Gore & Associates in January 2026.
Ownership category
akta.pro rank

Conformal Medical industry classification

Industry
Product category
Cardiac Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Left atrial appendage occlusion
  • Structural heart implants
  • Cardiac medical devices
  • Stroke prevention devices
  • Atrial fibrillation treatment

Where Conformal Medical is headquartered

Location

Headquarters

HQ city
Nashua
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Conformal Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

  1. Medical Device Sales (Planned): Conformal Medical is developing its CLAAS AcuFORM System for left atrial appendage occlusion. Once FDA pre-market approval is obtained, the company plans to generate revenue through direct sales of the LAAO device to hospitals and physicians performing stroke prevention procedures in atrial fibrillation patients.
  2. Clinical Trial Services: The company conducts clinical trials (CONFORM Pivotal Trial, GLACE Study) at hospital sites, generating revenue through clinical site management and device supply for investigational use.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Conformal Medical product offering

Product offering

Core offering

Conformal Medical develops the CLAAS AcuFORM System, a next-generation left atrial appendage occlusion (LAAO) implant for stroke prevention in patients with non-valvular atrial fibrillation. The device combines a proprietary conformable foam matrix with a nitinol endoskeleton and is offered in only two sizes, eliminating the need for transesophageal echocardiography, general anesthesia, and overnight hospitalization. The product is currently investigational and is being evaluated in the CONFORM Pivotal Trial and GLACE Study to support FDA pre-market approval.

Product overview

Conformal Medical is a privately held medical device company developing left atrial appendage occlusion (LAAO) technology for stroke prevention in atrial fibrillation patients. The core portfolio includes the CLAAS System (first foam-based LAAO device) and its next-generation iteration, the CLAAS AcuFORM System featuring a proprietary foam matrix with nitinol endoskeleton that requires only two sizes. Both devices are designed to seal the LAA without requiring anticoagulants and enable same-day procedures without general anesthesia or TEE. The company is actively conducting multiple clinical trials including the CONFORM Pivotal Trial and GLACE Study. Conformal Medical was acquired by W.L. Gore & Associates in early 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • CLAAS: The first & only LAAO device to use conformable foam to seal the left atrial appendage. Designed to reduce the risk of stroke without the need for anticoagulants.
  • CLAAS AcuFORM

Products and services

  • CLAAS AcuFORM System Next-generation left atrial appendage occlusion (LAAO) device featuring a proprietary foam matrix implant with nitinol endoskeleton designed to conform to patient anatomy. Offered in only two sizes, enabling simplified same-day procedures without general anesthesia or transesophageal echocardiography (TEE). Intended for stroke prevention in patients with non-valvular atrial fibrillation as an alternative to long-term oral anticoagulation. Currently investigational and limited to clinical trial use.

Quantifiable outcome

  • Same-day LAAO procedures without general anesthesia or overnight hospitalization
  • +2 more outcomes

Companies that use Conformal Medical

Customer profile

Segments3 records

Ideal customer profiles2 records

Conformal Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Conformal Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • W. L. Gore & AssociatescoreStrategic or Co-development Partner · 5 January 2026W.L. Gore & Associates entered into a definitive agreement to acquire Conformal Medical in January 2026 for an undisclosed amount. The acquisition expands Gore's endovascular portfolio and adds the CLAAS AcuFORM next-generation LAAO technology to Gore's cardiac product line. Transaction expected to close in early 2026 pending regulatory approval. Gore generates approximately $5.3 billion in annual revenues.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Conformal Medical competitors and assessment

Company assessment

Direct peers

  • Boston Scientific: Boston Scientific markets the WATCHMAN family of left atrial appendage closure devices, the leading LAAO product against which CLAAS AcuFORM is directly being compared in the CONFORM Pivotal Trial. Both companies target interventional cardiologists and electrophysiologists performing LAAO procedures for stroke prevention in non-valvular AFib patients.
  • Abbott: Abbott markets the Amplatzer Amulet LAA Occluder, the second major percutaneous LAAO device competing in the same clinical indication as Conformal's CLAAS AcuFORM. Both compete head-to-head in the CONFORM Pivotal Trial and target the same AFib stroke prevention patient population.
  • AtriCure: AtriCure's AtriClip is a surgical left atrial appendage exclusion device used as an alternative to percutaneous LAAO for stroke prevention in AFib patients. Both companies target the same LAA closure clinical indication, though AtriCure is primarily used in surgical epicardial settings rather than transcatheter procedures.

Emerging players

  • SentreHEART: SentreHEART developed the LARIAT suture-based LAA ligation system as an alternative approach to LAA closure. Both companies address the same underlying clinical need (LAA closure for AFib stroke prevention) using different mechanical approaches, and SentreHEART represents an emerging alternative modality.
  • Occlutech: Occlutech offers an LAA Occluder as part of its broader structural heart occlusion portfolio. Both companies target the same LAAO clinical indication for AFib-related stroke prevention, and Occlutech represents an emerging player with primarily European commercial reach.

Regional players

  • Lifetech Scientific: Lifetech Scientific (Shenzhen, China) markets the LAmbre LAA occluder, a transcatheter LAAO device competing in the same clinical indication as CLAAS AcuFORM. Lifetech is a regional player with primary commercial strength in Asia, while Conformal focuses on the US and EU markets.

Broad incumbents

  • W. L. Gore & Associates: W.L. Gore & Associates acquired Conformal Medical in January 2026 to add the CLAAS AcuFORM System to its endovascular portfolio. Gore is a broad incumbent in medical devices with established cardiac, vascular, and structural heart product lines that provide infrastructure for Conformal's commercialization.
  • Medtronic: Medtronic is a broad incumbent in cardiovascular devices with structural heart and cardiac surgery franchises. While Medtronic does not have a dedicated LAAO device competing head-to-head, its scale and hospital relationships make it a relevant comparable for the structural heart space Conformal operates in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Conformal Medical social profiles

Digital presence

Conformal Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Conformal Medical leadership team

Management profile

Number of profiles

Profiles10 records

Conformal Medical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Conformal Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Conformal Medical

What does Conformal Medical do?

Conformal Medical develops the CLAAS AcuFORM System, a next-generation left atrial appendage occlusion (LAAO) implant for stroke prevention in patients with non-valvular atrial fibrillation. The device combines a proprietary conformable foam matrix with a nitinol endoskeleton and is offered in only two sizes, eliminating the need for transesophageal echocardiography, general anesthesia, and overnight hospitalization. The product is currently investigational and is being evaluated in the CONFORM Pivotal Trial and GLACE Study to support FDA pre-market approval.

Is Conformal Medical a public or private company?

Conformal Medical is a private company. It is classified as corporate owned and is currently acquired.

When was Conformal Medical founded?

Conformal Medical was founded in 2016. It employs 51 to 100 people.

Where is Conformal Medical based?

Conformal Medical is headquartered in Nashua, United States, in the North America region.

How does Conformal Medical make money?

Two revenue lines are on record. Medical Device Sales (Planned) is the primary driver. The others are clinical Trial Services.

Who are Conformal Medical's main competitors?

Direct peers on record are Boston Scientific, Abbott and AtriCure. Emerging players are SentreHEART and Occlutech. Lifetech Scientific is listed as a regional player. Broad incumbents are W. L. Gore & Associates and Medtronic.

Does Conformal Medical have an API?

No public API is recorded for Conformal Medical.

What industry is Conformal Medical in?

Conformal Medical's product category is Cardiac Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireW. L. GORE & ASSOCIATES ÜBERNIMMT CONFORMAL MEDICAL UND BAUT SEINE PRÄSENZ IM BEREICH DER ENDOVASKULÄREN BEHANDLUNGEN AUSW. L. Gore & Associates announced it has entered into a definitive agreement to acquire Conformal Medical, Inc., a medtech company developing the investigational CLAAS® AcuFORM™ system, a next-generation left atrial appendage occlusion (LAAO) technology for stroke prevention in patients with non-valvular atrial fibrillation. The acquisition will expand Gore's endovascular portfolio and is expected to close in early 2026, pending regulatory approval. The deal combines Conformal's LAAO expertise with Gore's 50-year track record in cardiovascular medical technology and global commercial infrastructure.PR NewswireW. L. GORE & ASSOCIATES ACHÈTE CONFORMAL MEDICAL ET RENFORCE SA PRÉSENCE DANS LES TRAITEMENTS ENDOVASCULAIRESW. L. Gore & Associates announced a definitive agreement to acquire Conformal Medical, Inc., a medical device company developing the experimental CLAAS® AcuFORM™ left atrial appendage closure system, with the transaction expected to close in early 2026 pending regulatory approval. The AcuFORM system, featuring a nitinol endoskeleton and proprietary foam matrix, is designed to reduce the number of sizes required and enable same-day left atrial appendage closure procedures without general anesthesia or overnight hospitalization. The acquisition expands Gore's endovascular portfolio and complements its existing cardiac product line, aligning with the company's long-term strategy to invest in advanced medical technologies for treating cardiovascular conditions.Pulse 2.0W. L. Gore & Associates To Buy Conformal MedicalW. L. Gore & Associates agreed to acquire Conformal Medical, a developer of the investigational CLAAS AcuFORM left atrial appendage occlusion system. The deal is expected to close in early 2026, subject to regulatory approval. The device is in clinical testing and aims to simplify stroke prevention procedures.Medical Device NetworkGore acquires Conformal Medical to broaden endovascular portfolioW.L. Gore & Associates has acquired Conformal Medical to expand its endovascular portfolio, gaining the CLAAS AcuFORM system for left atrial appendage closure to reduce stroke risk in patients with atrial fibrillation. The transaction, with undisclosed terms expected to close in early 2026, positions Gore competitively against Boston Scientific and Abbott in the $5.5bn LAA closure devices market projected for 2034. Conformal recently closed a $32m Series D funding round, bringing its total funding to $161m, as the CLAAS device undergoes pivotal clinical trials comparing it against WATCHMAN and Amulet devices.MassDeviceW.L. Gore to acquire left atrial appendage device maker Conformal MedicalW.L. Gore & Associates announced an agreement to acquire Conformal Medical, a Nashua, New Hampshire-based developer of left atrial appendage occlusion devices, with the deal expected to close early this year pending regulatory approval. Conformal\'s investigational CLAAS AcuForm system uses a proprietary foam-based architecture and competes against Boston Scientific\'s Watchman and Abbott\'s Amplatzer Amulet in the LAAO space. Gore stated the acquisition advances its expansion into adjacent endovascular treatments and complements its existing cardiac products portfolio.PR NewswireW. L. GORE & ASSOCIATES TO ACQUIRE CONFORMAL MEDICAL, EXPANDING ITS PRESENCE IN ENDOVASCULAR TREATMENTSW. L. Gore & Associates announced it has entered into a definitive agreement to acquire Conformal Medical, Inc., a medical device company developing the investigational CLAAS AcuFORM System for left atrial appendage occlusion (LAAO) to reduce stroke risk in atrial fibrillation patients. The transaction, expected to close in early 2026 pending regulatory approval, will add Conformal's next-generation nitinol-based foam matrix implant technology to Gore's endovascular portfolio, with the potential to enable same-day LAAO procedures. Gore, which generates approximately $5.3 billion in annual revenues, stated the acquisition reflects its long-term commitment to developing and investing in breakthrough medical technologies.PR NewswireW. L. GORE & ASSOCIATES TO ACQUIRE CONFORMAL MEDICAL, EXPANDING ITS PRESENCE IN ENDOVASCULAR TREATMENTSW. L. Gore & Associates has entered into a definitive agreement to acquire Conformal Medical, Inc., a medical device company developing the investigational CLAAS AcuFORM System for left atrial appendage occlusion (LAAO). The acquisition, expected to close in early 2026 pending regulatory approval, will expand Gore's endovascular and cardiac portfolio with next-generation LAAO technology designed to enable same-day procedures without general anesthesia. The CLAAS AcuFORM System, currently in clinical testing, features a nitinol endoskeleton with a proprietary foam matrix intended to conform to a broader range of left atrial appendage anatomies.GoreW. L. Gore & Associates to Acquire Conformal Medical, Expanding its Presence in Endovascular TreatmentsW. L. Gore & Associates has entered into a definitive agreement to acquire Conformal Medical, Inc., a medical device company developing the investigational CLAAS AcuFORM System for left atrial appendage occlusion. The transaction, expected to close in early 2026 pending regulatory approval, will add next-generation LAAO technology to Gore's endovascular portfolio as a complement to its existing cardiac products. The CLAAS AcuFORM System, designed with a nitinol endoskeleton and proprietary foam matrix, has the potential to enable same-day LAAO procedures and targets the growing U.S. AFib patient population projected to exceed 12 million cases by 2030.ConformalmedicalW. L. GORE & ASSOCIATES TO ACQUIRE CONFORMAL MEDICAL,…W. L. Gore & Associates has entered into a definitive agreement to acquire Conformal Medical, Inc., an innovative medical device company developing the investigational CLAAS AcuFORM System for left atrial appendage occlusion. The transaction, expected to close in early 2026 pending regulatory approval, will add next-generation LAAO technology to Gore's endovascular and cardiac portfolio. The CLAAS AcuFORM System, designed in two sizes with a nitinol endoskeleton and proprietary foam matrix, has the potential to enable same-day LAAO procedures without general anesthesia or overnight hospitalization, addressing a growing patient population with non-valvular atrial fibrillation projected to exceed 12 million cases in the U.S. by 2030.Mpo-magEnrollment Begins in Trial Evaluating Conformal Medical’s LAAO DeviceConformal Medical Inc. has enrolled the first European Union patient in its CONFORM pivotal trial evaluating the CLAAS AcuFORM left atrial appendage occlusion device, with the debut procedure performed at Institut Cardiovasculaire Paris Sud in France. The trial plans to randomize approximately 1,600 patients at sites worldwide and is now more than 30% enrolled, aiming to generate pivotal data for stroke prevention in patients with non-valvular atrial fibrillation. The EU expansion marks a significant milestone for the company, positioning the CLAAS AcuFORM system for future commercialization and physician adoption across European healthcare markets.